These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 5107435)

  • 41. [Indications for and hazards of anticoagulant therapy].
    Straub PW
    Schweiz Med Wochenschr; 1970 Apr; 100(16):686-91. PubMed ID: 4258885
    [No Abstract]   [Full Text] [Related]  

  • 42. Anticoagulation therapy after recent bleeding: is it ever safe?
    White RH
    J Thromb Haemost; 2006 Nov; 4(11):2365-6. PubMed ID: 16981885
    [No Abstract]   [Full Text] [Related]  

  • 43. Hemorrhagic complications of anticoagulant therapy.
    Levine MN; Hirsh J
    Semin Thromb Hemost; 1986 Jan; 12(1):39-57. PubMed ID: 3515558
    [No Abstract]   [Full Text] [Related]  

  • 44. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Levine MN; Raskob G; Beyth RJ; Kearon C; Schulman S
    Chest; 2004 Sep; 126(3 Suppl):287S-310S. PubMed ID: 15383476
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anticoagulants: the state of the art.
    Gallus AS
    Aust Fam Physician; 1982 Jan; 11(1):14-22. PubMed ID: 7065989
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Ansell J; Hirsh J; Poller L; Bussey H; Jacobson A; Hylek E
    Chest; 2004 Sep; 126(3 Suppl):204S-233S. PubMed ID: 15383473
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk.
    Hawryluk GW; Austin JW; Furlan JC; Lee JB; O'Kelly C; Fehlings MG
    J Thromb Haemost; 2010 Jul; 8(7):1500-8. PubMed ID: 20403088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.
    Schulman S; Granqvist S; Holmström M; Carlsson A; Lindmarker P; Nicol P; Eklund SG; Nordlander S; Lärfars G; Leijd B; Linder O; Loogna E
    N Engl J Med; 1997 Feb; 336(6):393-8. PubMed ID: 9010144
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High complication and failure rates of anticoagulant therapy are unavoidable.
    Nitter-Hauge S; Dale J
    Z Kardiol; 1986; 75 Suppl 2():293-7. PubMed ID: 3727705
    [No Abstract]   [Full Text] [Related]  

  • 50. Current practice with vitamin K antagonist therapy.
    Kazmier FJ
    Mayo Clin Proc; 1974 Dec; 49(12):918-22. PubMed ID: 4216730
    [No Abstract]   [Full Text] [Related]  

  • 51. [Anticoagulant therapy. II. (Possibilities and limits)].
    Fischer M
    Med Welt; 1970 Apr; 14():620-6. PubMed ID: 5445111
    [No Abstract]   [Full Text] [Related]  

  • 52. Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin.
    González-Fajardo JA; Martin-Pedrosa M; Castrodeza J; Tamames S; Vaquero-Puerta C
    J Vasc Surg; 2008 Oct; 48(4):953-9. PubMed ID: 18639417
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy).
    Palareti G; Manotti C; DAngelo A; Pengo V; Erba N; Moia M; Ciavarella N; Devoto G; Berrettini M; Leali N; Poggi M; Legnani C; Musolesi S; Coccheri S
    Thromb Haemost; 1997 Dec; 78(6):1438-43. PubMed ID: 9423791
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reversal of antithrombotic agents.
    Bauer KA
    Am J Hematol; 2012 May; 87 Suppl 1():S119-26. PubMed ID: 22460529
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Periprocedural reversal and bridging of anticoagulant treatment.
    Levi M; Eerenberg E; Kamphuisen PW
    Neth J Med; 2011 Jun; 69(6):268-73. PubMed ID: 21868810
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Subtherapeutic oral anticoagulant therapy: frequency and risk factors.
    Rombouts EK; Rosendaal FR; van der Meer FJ
    Thromb Haemost; 2009 Mar; 101(3):552-6. PubMed ID: 19277419
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.
    Cohen AT; Davidson BL; Gallus AS; Lassen MR; Prins MH; Tomkowski W; Turpie AG; Egberts JF; Lensing AW;
    BMJ; 2006 Feb; 332(7537):325-9. PubMed ID: 16439370
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bleeding rates in patients older than 90 years of age on vitamin K antagonist therapy for nonvalvular atrial fibrillation.
    Tincani E; Baldini P; Crowther MA; Zanasi A; Ferrari P; Cenci AM; Rioli G
    Blood Coagul Fibrinolysis; 2009 Jan; 20(1):47-51. PubMed ID: 20523164
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The influence of anticoagulant therapy on the incidence of thromboembolism, hemorrhage and cardiac rupture in acute myocardial infarction; correlation of clinical and autopsy data in 100 cases.
    CAPECI NE; LEVY RL
    Am J Med; 1959 Jan; 26(1):76-80. PubMed ID: 13606155
    [No Abstract]   [Full Text] [Related]  

  • 60. Anticoagulants. Old and new.
    Levi M; Eerenberg ES; Kampuisen PW
    Hamostaseologie; 2011 Nov; 31(4):229-35. PubMed ID: 21687916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.